Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
US Stock Futures Jump on Reports of Preliminary US-Iran Peace Deal Despite Fed’s Hawkish Outlook 
DOJ Investigates Group Linked to Reid Hoffman Over E. Jean Carroll Lawsuit Funding 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
Bayer Rules Out Monsanto Spin-Off as Roundup Lawsuits Continue to Mount 
Russia Stocks End Flat as MOEX Index Hits New 52-Week Low; Gold Falls and Oil Mixed 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Asian Stocks Surge as Oil Prices Fall and Strong US Dollar Weighs on Markets 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
Italy’s Economy Outpaces Eurozone Peers as Investment Spending Fuels Growth 
Trump Questions USMCA Renewal as Trade Talks Continue 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
RFK Jr. Expands CDC Vaccine Advisory Panel's Scope Amid Legal Battles 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Bristol Myers Squibb has sued AstraZeneca for its antibody-based cancer treatment Imjudo, which it says infringes its patents for its drug Yervoy
According to Bristol Myer, Imjudo fights cancer in the same way as Yervoy.
Bristol Myers has previously sued AstraZeneca for patent infringement over the latter’s other cancer drug, Imfinzi.
AstraZeneca said it is aware of the complaint and will respond to it "at the appropriate time."
The FDA has also approved the immunotherapy Yervoy for the treatment of kidney, lung, colorectal, and other cancers. The FDA initially approved Yervoy in 2011 to treat melanoma.
In 2021, Bristol Myers sold over $2 billion worth of Yervoy.
AstraZeneca’s Imjudo was given FDA approval last year to be used in conjunction with Imfinzi to treat liver and lung cancer.
In the second lawsuit, Bristol Myers claimed that AstraZeneca had violated two patents on the use of antibodies to treat cancer and strengthen a patient's immune system.
Bristol Myers insists that AstraZeneca was aware of the patents, being on notice due to licensing discussions and the Imfinzi lawsuit.
The lawsuit seeks an unspecified amount of money for damages.
